Impact Biomedical Inc. IBO
Impact Biomedical Inc. (NYSE: IBO) is a life-science company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Linebacker-1/-2 (licensed to ProPhase Labs) | oncology, inflammation, neurology (potential) | small molecule | NA_NON_THERAPEUTIC |
| Equivir/Equivir G (licensed to ProPhase Labs) | upper respiratory wellness (OTC) | unclear | NA_NON_THERAPEUTIC |
| Laetose | reduced-calorie sugar / inflammatory-metabolic disease (potential) | unclear | NA_NON_THERAPEUTIC |
| Functional Fragrance Formulation (3F) | antimicrobial / insect repellent additive | unclear | NA_NON_THERAPEUTIC |
| Celios air purification | air filtration retail product | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.